Patent
The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
1. A method for treating a subject with a deficient plasma level of von Willebrand factor (VWF) cleaving protease activity, compared to a healthy subject, comprising administering a therapeutically effective dose of a pharmaceutical composition comprising a substantially-purified recombinant ADAMTS13 polypeptide that is at least 95% identical to SEQ ID NO:2 from amino acid position 75 to amino acid position 1427 to said subject under conditions such that the level of VWF cleaving protease activity is increased in said subject.
2. The method of claim 1 , wherein said subject with a deficient plasma level of VWF cleaving protease activity has familial thrombotic thrombocytopenic purpura (TTP).
3. The method of claim 1 , wherein said recombinant ADAMTS13 has an amino acid sequence that is at least 99% identical to SEQ ID NO:2 from amino acid position 75 to amino acid position 1427.
4. The method of claim 1 , wherein said recombinant ADAMTS13 is substantially purified using chromatography.
5. The method of claim 1 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein said pharmaceutical composition is formulated in an aqueous solution.
7. The method of claim 1 , wherein said pharmaceutical composition further comprises a drug or a hormone.
8. The method of claim 1 , wherein said pharmaceutical composition is free of proteins found in human plasma other than said ADAMTS13.
9. The method of claim 1 , wherein said deficient plasma level of VWF cleaving protease activity is caused by a mutation within the ADAMTS13 gene of said subject.